Jennison Associates
MACK

Jennison Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Jennison Associates’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-614,857
Closed -$35.3M – 771
2014
Q2 		$35.3M Sell
614,857
-127,313
-17% -$6.46M 0.03% 372
2014
Q1 		$29.4M Sell
742,170
-88,639
-11% -$3.79M 0.03% 403
2013
Q4 		$34.9M Buy
830,809
+137,939
+20% +$4M 0.03% 378
2013
Q3 		$20.7M Buy
692,870
+293,726
+74% +$10.3M 0.02% 430
2013
Q2 		$21.1M Buy
+399,144
New +$17.5M 0.02% 427

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Jennison Associates's MACK Position: Q3 2014 in Review

Jennison Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2014, closing a stake of 614,857 shares — an estimated $35.3M sold.

Jennison Associates first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $35.3M in Q2 2014. 132 funds tracked by Wall St. Rank hold MACK as of Q3 2014.

  • Jennison Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Jennison Associates sold 614,857 Merrimack Pharmaceuticals, Inc. shares in Q3 2014, an estimated $35.3M.
  • Jennison Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
  • Jennison Associates's Merrimack Pharmaceuticals, Inc. position peaked at $35.3M in Q2 2014.
  • 132 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2014.

Based on Jennison Associates's 13F filing for Q3 2014, filed 5 Nov 2014.